SPECIES: | Human |
---|---|
SOURCE SPECIES: | HEK293 cells |
SEQUENCE: | Thr 22 - Thr 457 |
FUSION TAG: | Tag free |
TESTED APPLICATIONS: | WB |
APPLICATIONS: | This recombinant protein can be used for WB. For research use only. |
PURITY: | >98% as determined by SDS-PAGE. |
---|---|
PREDICTED MOLECULAR WEIGHT: | 49 kDa |
PHYSICAL STATE: | Lyopholized |
BUFFER: | PBS, pH7.4 |
STORAGE CONDITIONS: | Lyophilized Protein should be stored at -20˚C or lower for long term storage. Upon reconstitution, working aliquots should be stored at -20˚C or -70˚C. Avoid repeated freeze-thaw cycles. |
ALTERNATE NAMES: | BACE1, ASP2, BACE, FLJ90568, HSPC104, KIAA1149, Memapsin-2 |
---|---|
ACCESSION NO.: | NP_036236.1 |
Beta-secretase 1 (BACE1) is also known as beta-site APP cleaving enzyme 1 (beta-site amyloid precursor protein cleaving enzyme 1), memapsin-2 (membrane-associated aspartic protease 2), and aspartyl protease 2 (ASP2), β-Secretase , and is a member of the peptidase A1 protein family, BACE1 is a type I integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi. BACE1 is an aspartic-acid protease important in the pathogenesis of Alzheimer's disease, and in the formation of myelin sheaths in peripheral nerve cells. The transmembrane protein contains two active site aspartate residues in its extracellular protein domain and may function as a dimer. This protease is responsible for the proteolytic processing of the amyloid precursor protein (APP). Generation of the 40 or 42 amino acid-long amyloid-β peptides that aggregate in the brain of Alzheimer's patients requires two sequential cleavages of the APP. Extracellular cleavage of APP by BACE creates a soluble extracellular fragment and a cell membrane-bound fragment referred to as C99. The elevation of BACE1 levels can be induced by amyloid plaques surrounding neurons at early stages of pathology before neuron death occurs, and may drive a positive-feedback loop in AD. |
ProSci Inc.始终开放以支持研究需求,同时确保我们员工的健康和安全。ProSci拥有广泛的冠状病毒SARS-CoV-2 重组蛋白和抗体产品组合, 并将继续积极开发新的冠状病毒 产品。此外,ProSci的定制抗体服务也保持开放状态,以支持研究团体开发 研究工具,诊断,疗法和疫苗。